• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

physIQ, CellCarta Collaborate on Study to Revolutionize Vaccine

by Jasmine Pennic 03/17/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
physIQ, CellCarta Collaborate on Study to Revolutionize Vaccine

What You Should Know:

– Today, digital medicine leader physIQ and CellCarta, a global leader in precision medicine services announced they are collaborating on a groundbreaking study that could revolutionize vaccine development.

– The strategic collaboration advances the detailed study of early, individualized human responses to vaccinations as pharma companies race to deliver safe, effective vaccines sooner.


physIQ, a pioneer in digital medicine, and CellCarta, a global leader in precision medicine services, announce a strategic collaboration to accelerate a more precise, personalized approach to vaccine development. With enrollment now complete, The VIII (Vaccine-Induced Inflammation Investigation) Study: The “Eight” Study and its Immunologic Response Sub-study seek to monitor individual differences in physiologic changes associated with immune system activation in patients receiving vaccinations, including those developed to combat diseases such as COVID-19.

Study Details

The study will use blood samples and medical-grade biosensors to continuously monitor and capture remote patient physiology data 24/7. It is made possible through CellCarta’s unique capabilities to comprehensively measure both humoral and cellular immune responses and physIQ’s proprietary platform using FDA-cleared, AI-based analytics to identify even the most subtle changes in an individual’s own unique physiology. Such changes in physiology and behavior can be detected within hours after a vaccine is administered and can be correlated to long-lasting immune responses.

Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness. The VII study is anticipated to provide the most rigorous, detailed evaluation of vaccine-induced reactogenicity (capacity of a vaccine to produce common, expected adverse reactions) and immunogenicity (the ability of cells/tissues to provoke an immune response) to date.

While earlier studies have shown that consumer wearables can monitor changes in people’s vital signs after vaccination, using medical-grade biosensors to measure vaccine-induced immune activation and subsequent inflammation assesses three distinct types of metrics: 1.) changes in physiologic variables (ECG, skin temperature and their derivatives) from that individual person’s established baseline; 2.) effect of modifications in individual routine behaviors (including multiple aspects of activity and sleep derived from accelerometers and vital signs); and, 3.) the interactions between these variables and how they deviate from that individual’s expected results. 

“We are excited to generate new potential insights into what makes a successful vaccination at the individual level,” says Dr. Scott Sugden, Immunologist and Principal Investigator of the study at CellCarta. “By evaluating the correlation between immediate physiological responses, antibody production and cellular immunity, the project will seek to define potential new metrics for rapid assessment of successful vaccination, which could ultimately lead to more effective vaccination strategies for everyone, including the most vulnerable, at-risk populations”.

Finding Results

Findings from the VIII Study are anticipated to be released in the coming months.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, behavior, Biosensors, Digital medicine, ecg, FDA, Pharma, PhysIQ, Precision Medicine, risk, Vital, Wearables

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Rethinking Big Data in 2024: How Healthcare Can Leverage Workforce Intelligence to Improve Care

Rethinking Big Data in 2024: How Healthcare Can Leverage Workforce Intelligence to Improve Care

Qualtrics and Epic Partner for Integrated Data-Driven Experience

Qualtrics and Epic Partner for Integrated Data-Driven Experience

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

Clover Health Exits CMS ACO REACH Program to Focus on Medicare Advantage

Clover Health Exits CMS ACO REACH Program to Focus on Medicare Advantage

Cigna to Acquire Express Scripts for $67B: 5 Things to Know

Cigna and Humana Merger Talks Could Face Antitrust Scrutiny

RNSA23: Cleveland Clinic and Canon Partner to Pioneer Next-Gen Imaging Technologies

RSNA23: Cleveland Clinic and Canon to Establish Comprehensive Imaging Research Center

Automating Implant Orders: A Turning Point in Healthcare’s Digital Transformation

Automating Implant Orders: A Turning Point in Healthcare’s Digital Transformation

Consumers Believe Generative AI Can Revolutionize Healthcare

71% of Consumers Believe Generative AI Can Revolutionize Healthcare

NCQA Launches Virtual Care Accreditation Pilot

NCQA Launches Virtual Care Accreditation Pilot

Novant Health Acquires Three Tenet Hospitals in South Carolina for $2.4 Billion

M&A: Novant Health Acquires 3 Tenet Hospitals in South Carolina for $2.4B

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |